Skip to NavigationSkip to content

News

0
Stem cells
EMA says Chiesi’s blindness treatment Holoclar is a ‘major step forward’
0
Merck image
First cancer inhibitor of its kind to be included in deal potentially worth $375 million
0
Roche image
Kadcyla shows no additional breast cancer benefit and firm pulls plug on major Alzheimer’s trial
0
GSK image
HZ/su now considered a strong competitor to Merck’s Zostavax

Features

Ian Goldin, director, Oxford Martin School, University of Oxford speaks at the c

Tom Robinson reports from the Financial Times conference that entertained some ‘provocative’ insights